Views & Analysis What doctors say about changes to the Cancer Drugs Fund Assessing HCPs’ social media comments about the new approach to cancer drug funding.
Oncology ESMO26: Taiho Oncology on improving the lives of patients wi... Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
